Advertisement
LONDON and PHILADELPHIA, Oct. 1 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period April - June 2008. The quarterly Pharma Matters reports cover all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping SystemSM.
Advertisement
Movers and Shakers - This report covers the US generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q2 2008 report includes:
To learn more about companies making their mark on the US generics market, click on this link to read the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/movers_shakers_apr-jun_08.pdf
Who is Making the Biggest Splash? - A Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the 15 listed organizations that have made the biggest impact as the leading sources of information on medical research from April - June 2008 are:
To see the complete list, as well as analysis and methodology, click to read the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/making-a-splash-june2008.pdf
The Ones to Watch - A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on the strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q2 2008, the top five most promising drugs launched or receiving approval were:
More analysis, as well as information on drugs entering clinical Phases I, II and III, are available in the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/totw_apr-jun_08.pdf
To sign up for the Thomson Reuters Pharma Matters series of publications visit: scientific.thomson.com/pharma/forms/matters/
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.
-- The wave of M&A activity which had already been noted in the previous quarter continued unabated. The headline action for the sector was undoubtedly Daiichi Sankyo's (Japan) proposed acquisition of Ranbaxy (India). -- During the second quarter of 2008, final approvals were issued on 142 'A'-rated ANDAs, up from 134 the quarter before. -- Seven new products (three combination products and four single active ingredient products) were subjected to paragraph IV challenges for the first time in Q2 2008, in comparison to the challenges made to 11 new products in the first quarter of 2008. -- During the second quarter of 2008, the largest number of ANDA approvals went to India-based companies. Seventeen different India-based corporations received a total of 52 final ANDA approvals. -- In the same time period, 26 US-based companies received a total of 45 approvals, putting the US in second place for this quarter. -- Sun Pharmaceutical of India received 11 final ANDA approvals, the greatest number of any individual group in Q2 2008. A number of those ANDAs were related to the compound amitriptyline.
SOURCE Thomson Reuters
